Nexalis Therapeutics Limited (ASX:NX1)

Australia flag Australia · Delayed Price · Currency is AUD
0.0230
+0.0040 (21.05%)
At close: Apr 17, 2026
Market Cap5.82M -19.3%
Revenue (ttm)986.43K +145.5%
Net Income-1.62M
EPS-0.01
Shares Out253.04M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume34,079
Average Volume110,057
Open0.0200
Previous Close0.0190
Day's Range0.0200 - 0.0230
52-Week Range0.0170 - 0.0480
Beta0.06
RSI51.86
Earnings DateMay 22, 2026

About Nexalis Therapeutics

Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as InhaleRx Limited and changed its name Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is headquartered in Melbourne, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol NX1
Full Company Profile

Financial Performance

In 2025, Nexalis Therapeutics's revenue was 986,434, an increase of 145.50% compared to the previous year's 401,811. Losses were -1.62 million, 33.9% more than in 2024.

Financial Statements